CAMBRIDGE, Mass., June 20, 2014 (GLOBE NEWSWIRE) -- Blueprint Medicines today announced that Kyle Kuvalanka, chief business officer, will present a company overview at the JMP Securities Healthcare Conference on Tuesday, June 24, 2014 at 4:00 p.m. EDT at the Westin New York Grand Central Hotel in New York, NY.
About Blueprint Medicines
Blueprint Medicines is a patient-driven oncology company developing highly selective kinase inhibitors for genomically defined cancer patients. Led by a management team and advisors with world renowned expertise in cancer genomics, drug discovery, and clinical oncology, Blueprint has developed a platform that combines genomics with a novel small molecule library of kinase inhibitors, enabling Blueprint to rapidly develop potent, highly selective compounds against clear genomic driver targets. Founded in 2011, Blueprint is privately held and initially backed by Third Rock Ventures and Fidelity BioSciences. For more information, please visit BlueprintMedicines.com.
Beth DelGiacco Stern Investor Relations, Inc. 212-362-1200